JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 25, 2007; DOI: 10.1124/jpet.107.120600


0022-3565/07/3223-1003-1012$20.00
JPET 322:1003-1012, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.120600v1
322/3/1003    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izco, M.
Right arrow Articles by Colado, M. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izco, M.
Right arrow Articles by Colado, M. I.

NEUROPHARMACOLOGY

Mice with Decreased Cerebral Dopamine Function following a Neurotoxic Dose of MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") Exhibit Increased Ethanol Consumption and Preference

Maria Izco, Ivanny Marchant1, Isabel Escobedo, Ines Peraile, Mercedes Delgado, Alejandro Higuera-Matas, Oscar Olias, Emilio Ambrosio, Esther O'Shea, and M. Isabel Colado

Departamento de Farmacologia, Facultad de Medicina (M.I., I.M., I.E., I.P., E.O., M.I.C.) and Instituto Pluridisciplinar (M.D.), Universidad Complutense, Madrid, Spain; and Facultad de Psicologia, Universidad Nacional de Educación a Distancia, Madrid, Spain (A.H.-M, O.O., E.A.)

MDMA (3,4-methylenedioxymethamphetamine, "ecstasy") administration to mice produces relatively selective long-term neurotoxic damage to dopaminergic pathways. There is strong evidence indicating that the dopamine system plays a key role in the rewarding effects of ethanol and modulates ethanol intake. Using a two-bottle free-choice paradigm, we examined the voluntary consumption and preference for ethanol in mice deficient in cerebral dopamine concentration and dopamine transporter density by previous repeated MDMA administration. The current study shows that mice pre-exposed to a neurotoxic dose of MDMA exhibited a higher consumption of and preference for ethanol compared with saline-treated animals. The D1 receptor full agonist SKF81297 [(6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide)] attenuated the enhanced ethanol intake, an effect that was reversed by SCH23390 [((R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride], a D1 receptor antagonist. MDMA-exposed mice also showed a reduced release of basal dopamine in the nucleus accumbens compared with saline-injected animals and a modest increase in D1 receptor density in caudate-putamen and nucleus accumbens. Intraperitoneal administration of ethanol elevated extracellular dopamine release in the nucleus accumbens of saline-treated mice, but this effect was almost abolished in MDMA-treated mice. Differences between saline- and MDMA-treated animals did not appear to be secondary to changes in acute ethanol clearance. These results indicate that mice with reduced dopamine activity following a neurotoxic dose of MDMA exhibit increased ethanol consumption and preference and suggest that animals might need to consume more alcohol to reach the threshold for the rewarding effects of ethanol.


Received for publication January 26, 2007
Accepted May 24, 2007.

Address correspondence to: Maria Isabel Colado, Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Madrid 28040, Spain. E-mail: colado{at}med.ucm.es







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.